ResearchHub Text Logo
Home
Live
new
RH Journal
ResearchCoin
Grants
Funding
Browse
Journals
Hubs
Tools
Lab Notebook
Beta
Reference Manager
Resources
Verify IdentityVerified
CommunitySupportAbout
TermsPrivacyIssuesDocs
Paper
RH Logo
RH LogoRH Logo
Paper
0
Paper
Conversation
Grants
Reviews
Document
Download
Flag content
0

AML-609 Gilteritinib-Based Combinations Improve Survival and Enhances Allogenic Transplant Eligibility in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Canadian Single Center Experience

Oncology
Internal Medicine
Hematology
Show More
Save
TipTip
Document
Download
Flag content
0
TipTip
Save
Document
Download
Flag content
Paper
Conversation
Grants
Reviews

Abstract

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.